Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
201, Devavrata, Sector 17, Vashi,
Navi Mumbai - 400 703, India
T: +91 22 2789 2924
F: +91 22 2789 2942

Date: June 10, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 **Scrip Code: 544292, ISIN: INE013P01021**	**National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 **Symbol: ONESOURCE**

Dear Sir/ Madam,

Reg: **Disclosure under Reg 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations)**

Subject: **US-FDA compliance status for OneSource: Unit 2: Doddaballapura, Bangalore**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled:

"OneSource's Flagship Drug-Device Combination Facility in Bangalore Maintains USFDA Compliance Status."

The above release will be disseminated to the media and is also being uploaded on the Company's website at www.onesourcecdmo.com.

Please take the above information on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Digitally signed by Trisha A
Date: 2025.06.10 08:21:33 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

onesource

Press Release
June 10, 2025

OneSource's flagship drug-device combination facility in Bangalore maintains its USFDA compliance status

Bangalore, India, June 10, 2025 — OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma pure-play CDMO, announced that its flagship facility in Bangalore, India, has received a "Voluntary Action Indicated" (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.

Following an inspection of the company's flagship facility from March 20 to March 28, 2025, the USFDA issued a Form 483 with four observations. Based on the company's comprehensive response and commitments, the agency has classified the inspection outcome as Voluntary Action Indicated (VAI), officially closing the inspection.

Neeraj Sharma, Managing Director & CEO, said *" The successful closure of our latest USFDA inspection is a pivotal moment in our journey, and we are very pleased with this outcome demonstrating our exemplary compliance status. Our flagship facility, Unit 2, is the cornerstone of our manufacturing capabilities in Drug Device Combinations (DDC), biologics drug substances, and complex injectables. This milestone validates our deep-rooted commitment to quality and is crucial as our partners prepare to launch key GLP-1 products in late FY26. We are excited to advance into our next significant commercial phase."*

About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors	**Corporate Communication**
Anurag Bhagania CFO Email: Anurag.bhagania@onesourcecdmo.com **Tejaswani Fotedar** Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 **Abhilash Mukherjee:** +91 89044 28907 Email: corpcomm@onesourcecdmo.com **PR Consultancy** Adfactors PR **Janhavi Bellare**: +91 93228 54508 Email: Janhavi.bellare@adfactorspr.com **Syed Talal:** +91 99876 19679 Email: syed.talal@adfactorspr.com